DTRM Biopharma

About DTRM Biopharma

Based in Hangzhou, China, DTRM Biopharma is a clinical-stage biopharmaceutical company that has been operating since its establishment in 2011 by Dr. He Wei and Zhejiang Hisun Pharmaceutical. The company directs its efforts towards developing innovative therapies for cancer patients with unmet medical needs. DTRM Biopharma's business strategy revolves around the development of proprietary drug candidates, with a focus on bringing them through clinical trials to address voids in cancer treatment. The company's financial structure is supported by venture capital, having secured a significant $60.5 million in a Series A funding round in late 2017, followed by a later-stage venture round in January 2021. Key investors include BVCF, Advantech Capital Partners, and Green Pine Capital Partners.

The core of DTRM Biopharma's research and development is its pipeline of oral doublet and triplet therapy technologies. A key candidate is DTRMWXHS-12, a Bruton's tyrosine kinase (BTK) inhibitor. This drug is being investigated both as a monotherapy and in combination with other agents for treating B-cell lymphomas and chronic lymphocytic leukemia (CLL). The company is exploring fixed-dose combinations, such as DTRM-505 (a dual therapy) and DTRM-555 (a triple therapy), which are designed to turn terminal cancers into chronically manageable conditions. These combination therapies leverage a synthetic lethality approach, concurrently inhibiting multiple pathways like BTK and mTOR to synergistically target malignant B-cells. Clinical trials for these candidates are underway in both the United States and China, with collaborations at institutions like the University of Pennsylvania, Mayo Clinic, and Peking University Cancer Hospital.

The company's approach is distinguished by its simultaneous drug development operations in the US and China, managed by a leadership team with extensive experience. This dual-country strategy allows DTRM to conduct multinational clinical trials. The company holds a portfolio of over 70 patents in the U.S., China, and other regions, protecting its novel drug candidates and combination therapies. This intellectual property is central to its model of creating value through the development of patent-protected, first-in-class oral treatments for various cancers and immune diseases.